Clovertex’s April 2025 Target of the Month is the neonatal Fc receptor (FcRn), following the U.S. FD...
Clovertex’s March Target of the Month is GSPT1, a translation termination factor that plays a vital ...
Clovertex's February Target of the Month is the farnesoid X receptor (FXR), a nuclear receptor that ...
Clovertex’s January Target of the Month is Dopamine D2 Receptor (D2R), highlighted by Johnson & John...
Clovertex’s Target of the Year 2024 is the Gastric Inhibitory Polypeptide Receptor (GIPR), which has...
Clovertex’s December Target of the Month is the Dystrophin-Glycoprotein Complex (DGC), inspired by a...
Clovertex’s November Target of the Month is Ninjurin 1 (NINJ1), selected in light of a recent cryo-E...
Following this year’s Nobel Prize in Chemistry for breakthroughs in protein structure prediction and...
We are pleased to announce that PTH1R (Parathyroid Hormone 1 Receptor) is Clovertex's Target of the ...
We are excited to announce that Isocitrate Dehydrogenase 1(IDH1) has been selected as Clovertex’s Ta...